ORCID Profile
0000-0002-7005-1546
Current Organisations
GfBU-Consult Gesellschaft für Umwelt- und Managementberatung mbH
,
University of Warwick
,
University of Oxford
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Springer Science and Business Media LLC
Date: 17-12-2020
Publisher: Elsevier BV
Date: 03-2021
Publisher: Wiley
Date: 18-01-2013
Abstract: Two new chelate ligands, 6‐methyl‐6‐(pyridin‐2‐yl)‐1,4‐bis[(pyridin‐2‐yl)methyl]‐1,4‐diazepane ( 4a ) and 6‐methyl‐6‐(pyridin‐2‐yl)‐1,4‐bis[2‐(pyridin‐2‐yl)ethyl]‐1,4‐diazepane ( 4b ), were synthesized from pyridine‐derived precursors in three‐step procedures. Both ligands have N 5 donor sets consisting of two tertiary amine and three pyridyl N atoms. Complexation with FeCl 2 or FeBr 2 in MeOH followed by anion exchange with ( n Bu 4 N)PF 6 gave the complexes [Fe( 4a )X]PF 6 and [Fe( 4b )X]PF 6 (X = Cl, Br) in moderate‐to‐good yields. The coordination geometry around the iron(II) centre, as determined by single‐crystal X‐ray diffraction, is strongly distorted octahedral for ligand 4a and more regular for ligand 4b . Magnetic susceptibility measurements show the complexes to contain high‐spin iron(II) over the whole range of temperatures (2 T 300 K). DFT calculations for the complexes of ligands 4a and 4b reproduce the high‐spin ground state and suggest that exchange of the halide ligand for ligands that exhibit some degree of π‐type interaction could induce SCO behaviour. Also, calculations of the zero‐field splitting (ZFS) parameters of these complexes rationalize the observed sign change on the basis of different degrees of structural distortion imparted by ligands 4a and 4b .
Publisher: Elsevier BV
Date: 08-2020
Publisher: Springer Science and Business Media LLC
Date: 21-05-2021
Publisher: Springer Science and Business Media LLC
Date: 17-12-2020
Publisher: Elsevier BV
Date: 12-2020
Publisher: Frontiers Media SA
Date: 07-02-2022
DOI: 10.3389/FIMMU.2022.795463
Abstract: Protection from liver-stage malaria requires high numbers of CD8+ T cells to find and kill Plasmodium -infected cells. A new malaria vaccine strategy, prime-target vaccination, involves sequential viral-vectored vaccination by intramuscular and intravenous routes to target cellular immunity to the liver. Liver tissue-resident memory (TRM) CD8+ T cells have been shown to be necessary and sufficient for protection against rodent malaria by this vaccine regimen. Ultimately, to most faithfully assess immunotherapeutic responses by these local, specialised, hepatic T cells, periodic liver s ling is necessary, however this is not feasible at large scales in human trials. Here, as part of a phase I/II P. falciparum challenge study of prime-target vaccination, we performed deep immune phenotyping, single-cell RNA-sequencing and kinetics of hepatic fine needle aspirates and peripheral blood s les to study liver CD8+ TRM cells and circulating counterparts. We found that while these peripheral ‘TRM-like’ cells differed to TRM cells in terms of previously described characteristics, they are similar phenotypically and indistinguishable in terms of key T cell residency transcriptional signatures. By exploring the heterogeneity among liver CD8+ TRM cells at single cell resolution we found two main subpopulations that each share expression profiles with blood T cells. Lastly, our work points towards the potential for using TRM−like cells as a correlate of protection by liver-stage malaria vaccines and, in particular, those adopting a prime-target approach. A simple and reproducible correlate of protection would be particularly valuable in trials of liver-stage malaria vaccines as they progress to phase III, large-scale testing in African infants. We provide a blueprint for understanding and monitoring liver TRM cells induced by a prime-target malaria vaccine approach.
Publisher: Elsevier BV
Date: 2021
Publisher: Elsevier BV
Date: 09-2021
Publisher: Springer Science and Business Media LLC
Date: 06-05-2021
Location: Germany
Location: Germany
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
Location: United Kingdom of Great Britain and Northern Ireland
No related grants have been discovered for Richard Morter.